Objective
Sudden cardiac arrest affects up to 1 million people in US and Europe per year, being the 3rd leading cause of death globally. Despite international medical efforts, 9 out of 10 people will die after a cardiac arrest (average survival rate 10.6%). In the European Union, cardiovascular disease costs to the economy more than €192 billion annually.
Emergency teams suffer the most with the extremely high mortality and morbidity rates due to cardiac arrest worldwide. Currently, medical assistive devices play a limited role on teams’ diagnostics and therapeutic actions during rescue emergencies. Nevertheless, the defibrillation/CPR devices global market was valued at $1.7B in 2014 and is expected to grow until 2019 with a CAGR of 8% reflecting a strong market demand.
pCPR is a portable, precise and personalized medical device to properly assist emergency teams during sudden cardiac arrest emergencies. It consists of a thoracic pad with sensors that doctors, nurses and paramedics apply directly to the patient linked to a new monitor display and defibrillator to support and guide their critical decision-making and patient-specific emergent therapy.
The value proposition of pCPR is based on emergency end-users’ feedback and experts’ calls for action, through a lean fast-to-market strategy, delivering unique selling points:
- Adaptive physiological feedback (disruptive innovation);
- Focus on cerebral oxygen saturation, temperature and tcCO2 (new target indicators);
- Clinical reasoning algorithms (cognitive aids at point of care);
- Cardiac/Neurologic outcomes guidance (assisting device);
- Data management for Quality control (analytics);
- Exclusively non-invasive sensors (technology);
pCPR wants to be one of the leading assistive device for emergency teams worldwide in a 5-years’ time frame, building upon its patented thoracic pad and combined sensing capabilities to deliver better cost-effective patient care and health outcomes, namely the cardiac arrest survival rate.
Fields of science
Programme(s)
- H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
- H2020-EU.3.1.4. - Active ageing and self-management of health
- H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
- H2020-EU.3.1.6. - Health care provision and integrated care
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
3000 019 COIMBRA
Portugal
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.